Publications

Categories
Search
Preclinical
October 25, 2024
AACR-EORTC-NCI
ZW220, a NaPi2b-directed TOPO1i ADC, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in NHPs
Andrea Hernández Rojas
Preclinical
October 24, 2024
AACR-EORTC-NCI
Beyond ADC Target Expression: Understanding ADC Properties and Pharmacology
Raffaele Colombo
Preclinical
October 23, 2024
Cancer Discovery
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo et al.
Preclinical
October 23, 2024
AACR-EORTC-NCI
ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models
Madera et al.
Preclinical
September 4, 2024
World Bispecific Summit
Leveraging Azymetric to Optimally Format T-Cell Engagers and Bispecific ADCs
Paul Moore
Preclinical
August 21, 2024
ACS
Design and selection of the novel camptothecin analog ZD06519: A payload optimized for antibody-drug conjugates
Brant et al.
Preclinical
August 7, 2024
Immuno-Oncology Summit
Building Differentiated & Next Generation T Cell Engagers to Improve Responses in Difficult-to-Treat Tumors.
Nicole Afacan
Preclinical
June 23, 2024
ADCS National Medicinal Chemistry Symposium
Development of a Novel TOPO1i ADC Platform: From Concept to Pipeline Application
Mark Petersen
Preclinical
May 16, 2024
PEGS
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Dunja Urosev
Preclinical
May 16, 2024
PEGS
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and antitumor responses in hard-to-treat cancers
Newhook et al.
Preclinical
April 17, 2024
Festival of Biologics
Next Generation Trispecific T Cell Engagers (TriTCE) Designed to Improve Treatment Responses in Oncology
Genevieve Desjardins
Preclinical
April 10, 2024
AACR
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
Newhook et al.